Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,840 | 3,960 | 06.06. | |
3,840 | 3,960 | 06.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | BTIG hält an Kursziel von 15 US-Dollar für Rezolute-Aktie nach Studien-Update fest | 1 | Investing.com Deutsch | ||
28.05. | BTIG maintains $15 target on Rezolute stock following trial update | 2 | Investing.com | ||
REZOLUTE Aktie jetzt für 0€ handeln | |||||
14.05. | Rezolute GAAP EPS of -$0.27 | 2 | Seeking Alpha | ||
13.05. | Rezolute, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | Rezolute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update | 82 | GlobeNewswire (Europe) | sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy... ► Artikel lesen | |
25.04. | Rezolute, Inc. Announces Closing of Underwritten Offering | 3 | GlobeNewswire (USA) | ||
23.04. | Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants | - | RTTNews | ||
23.04. | Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December | 2 | Benzinga.com | ||
23.04. | Rezolute gets positive recommendation from IDMC to continue Ersodetug study | 1 | Seeking Alpha | ||
23.04. | Rezolute stock rises after pricing $90M securities offering | 1 | Seeking Alpha | ||
23.04. | Rezolute kündigt Aktien- und Optionsscheinangebot über 90 Millionen US-Dollar an | 3 | Investing.com Deutsch | ||
23.04. | Rezolute, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | Rezolute's sunRIZE trial to proceed without changes | 3 | Investing.com | ||
23.04. | Rezolute, Inc.: Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
28.03. | Rezolute, Inc. - 8-K, Current Report | - | SEC Filings | ||
26.03. | Rezolute expands board with biopharma veteran Erik Harris | 1 | Investing.com | ||
26.03. | Rezolute, Inc.: Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors | 1 | GlobeNewswire (USA) | ||
13.02. | JMP Securities lifts Rezolute stock target to $9, maintains rating | 14 | Investing.com | ||
12.02. | Rezolute GAAP EPS of -$0.22 beats by $0.03 | 15 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
EXELIXIS | 37,400 | -0,93 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution | ||
VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |